Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th

Actuate Therapeutics’ (NASDAQ:ACTU) lock-up period will end on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Actuate Therapeutics Stock Up 2.3 %

NASDAQ:ACTU opened at $9.03 on Monday. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73. The stock’s fifty day simple moving average is $8.46.

Institutional Investors Weigh In On Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new position in shares of Actuate Therapeutics (NASDAQ:ACTU) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned 0.06% of Actuate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.